BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Down on Analyst Downgrade

Key Points

• BioMarin shares fell sharply after RBC cut its price target from $62 to $60 and maintained a sector-perform rating; the stock opened at $53.06 versus a prior close of $57.44.
• BioMarin’s third-quarter results were strong, with revenue rising 32% year over year to $1.025 billion and adjusted EPS of $0.23 beating expectations for a loss. Growth was driven by metabolic- and skeletal-condition treatments.
• Lowered 2026 guidance remains a concern: EPS is now expected at $2.80–$3.10 and revenue at $3.8–$3.9 billion, both below consensus, although analysts maintain a “Moderate Buy” consensus and see longer-term potential from pipeline expansion.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report)'s share price gapped down before the market opened on Tuesday after Royal Bank Of Canada lowered their price target on the stock from $62.00 to $60.00. The stock had previously closed at $57.44, but opened at $53.06. Royal Bank Of Canada currently has a sector perform rating on the stock. BioMarin Pharmaceutical shares last traded at $55.1030, with a volume of 411,376 shares changing hands.

Several other analysts have also issued reports on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $86.00 price objective on shares of BioMarin Pharmaceutical in a report on Tuesday, October 20th. Wall Street Zen lowered BioMarin Pharmaceutical from a "buy" rating to a "hold" rating in a research report on Saturday. BMO Capital Markets reaffirmed an "outperform" rating on shares of BioMarin Pharmaceutical in a research report on Wednesday, September 16th. Barclays raised their price target on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 14th. Finally, Morgan Stanley reduced their price target on BioMarin Pharmaceutical from $124.00 to $122.00 and set an "overweight" rating for the company in a report on Wednesday, October 21st. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $88.09.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and broadly in line with estimates. Growth was led by a 44% increase in metabolic-condition revenue and a 12% increase in skeletal-condition revenue. Adjusted EPS of $0.23 substantially exceeded the consensus estimate for a loss of approximately $0.08. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company expanded its pipeline with a new investigational Fabry-disease asset and reported a May 30, 2027, FDA action date for VOXZOGO in hypochondroplasia. These developments support BioMarin’s longer-term growth prospects. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Citi reiterated a Buy rating, arguing that the timing-related setback does not undermine BioMarin’s long-term potential and citing approximately 32% upside. Other commentary described the stock as potentially undervalued following the Fabry deal and mixed guidance. BioMarin’s Timing-Related Setback Masks Long-Term Growth Potential
• Negative Sentiment: BioMarin lowered fiscal 2026 EPS guidance to $2.80–$3.10, below the $3.32 analyst consensus, and set revenue guidance at $3.8–$3.9 billion versus a $3.9 billion consensus. The lower outlook may outweigh the quarterly earnings beat in the near term. BMRN Q3 Deep Dive
• Neutral Sentiment: Management characterized the outlook issue as primarily related to order timing, while acquired IPR&D charges also affected earnings expectations. Investors will likely focus on whether demand timing normalizes and whether the expanded pipeline generates future growth.

Institutional Trading of BioMarin Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in BMRN. Parkside Financial Bank & Trust raised its stake in shares of BioMarin Pharmaceutical by 70.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company's stock valued at $26,000 after acquiring an additional 187 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in BioMarin Pharmaceutical in the 2nd quarter worth approximately $39,000. Keating Financial Advisory Services Inc. bought a new stake in BioMarin Pharmaceutical during the second quarter worth approximately $56,000. Root Financial Partners LLC bought a new stake in BioMarin Pharmaceutical during the third quarter worth approximately $88,000. Finally, Parallel Advisors LLC grew its holdings in BioMarin Pharmaceutical by 33.9% during the first quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company's stock valued at $100,000 after purchasing an additional 448 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company's stock.

BioMarin Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. The firm has a fifty day simple moving average of $60.43 and a 200 day simple moving average of $58.46. The company has a market cap of $10.61 billion, a price-to-earnings ratio of 148.14, a P/E/G ratio of 0.61 and a beta of 0.22.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.31. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter last year, the firm posted $0.12 earnings per share. The company's quarterly revenue was up 32.0% compared to the same quarter last year. On average, sell-side analysts expect that BioMarin Pharmaceutical Inc. will post 2.59 earnings per share for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company's research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin's marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.